Andrew G Bushmakin
Overview
Explore the profile of Andrew G Bushmakin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
1373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gossec L, Walsh J, Sengupta R, Bushmakin A, Cappelleri J, Yndestad A, et al.
Rheumatol Ther
. 2024 Dec;
12(1):85-98.
PMID: 39671076
Introduction: Fatigue is a key symptom in patients with ankylosing spondylitis (AS). The objective of this analysis was to estimate the median time to initial and stable improvement events in...
2.
Draelos Z, Bushmakin A, Ghosh P, Xenakis J, Cappelleri J
Int J Dermatol
. 2024 Aug;
63(12):e375-e382.
PMID: 39160651
Background: Pruritus is a common, bothersome symptom for patients with mild-to-moderate plaque psoriasis (PsO), yet no validated scale assesses it in this patient population. We aimed to validate the Peak...
3.
Navarro-Compan V, Deodhar A, Bahiri R, Bushmakin A, Cappelleri J, Rammaoui J
Arthritis Res Ther
. 2024 May;
26(1):105.
PMID: 38790040
Background: Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Time to improvement in core domains of AS was estimated in tofacitinib-treated patients with AS. Methods:...
4.
Schnitzer T, Conaghan P, Berenbaum F, Abraham L, Cappelleri J, Bushmakin A, et al.
Adv Rheumatol
. 2024 Apr;
64(1):31.
PMID: 38650049
Background: To illustrate how (standardised) effect sizes (ES) vary based on calculation method and to provide considerations for improved reporting. Methods: Data from three trials of tanezumab in subjects with...
5.
Ren J, Bushmakin A, Cislo P, Abraham L, Cappelleri J, Dworkin R, et al.
J Biopharm Stat
. 2023 Nov;
:1-13.
PMID: 37982583
Objectives: The FDA recommends the use of anchor-based methods and empirical cumulative distribution function (eCDF) curves to establish a meaningful within-patient change (MWPC) for a clinical outcome assessment (COA). In...
6.
Magrey M, Cheng-Chung Wei J, Yndestad A, Bushmakin A, Cappelleri J, Dina O, et al.
Arthritis Care Res (Hoboken)
. 2023 Nov;
76(3):359-365.
PMID: 37909386
Objective: We examined the relationships of work productivity and activity impairment with key patient-reported outcomes (PROs) assessing pain, disease activity, and health-related quality of life (HRQoL) in patients with ankylosing...
7.
Yosipovitch G, Gooderham M, Stander S, Fonacier L, Szepietowski J, Deleuran M, et al.
Am J Clin Dermatol
. 2023 Aug;
25(1):127-138.
PMID: 37624488
Background: Abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, improved itch severity, sleep, and work productivity versus placebo in patients with moderate-to-severe atopic dermatitis. Objective: The aim of this study...
8.
Kristensen L, Navarro-Compan V, Magrey M, Bushmakin A, Cappelleri J, Yndestad A, et al.
Rheumatol Ther
. 2023 Jun;
10(4):1073-1087.
PMID: 37351781
Introduction: Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Using mediation modelling, we describe interrelationships between fatigue, pain, morning stiffness, C-reactive protein (CRP) and tofacitinib...
9.
Schnitzer T, Robinson R, Viktrup L, Cappelleri J, Bushmakin A, Tive L, et al.
J Clin Med
. 2023 Apr;
12(7).
PMID: 37048816
Patients often take opioids to relieve osteoarthritis (OA) pain despite limited benefits and potential harms. This study aimed to compare cross-sectional perspectives of patients that were taking prescription opioid (N...
10.
Abraham L, Dworkin R, Turk D, Markman J, Williams D, Bushmakin A, et al.
Clin J Pain
. 2023 Feb;
39(4):159-165.
PMID: 36806283
Objectives: To better understand the relationships among treatment, pain, and physical function (PF). Methods: Data were collected from 2 published randomized clinical trials of osteoarthritis patients who received tanezumab or...